Summary
Eight patients, four male and four female, were treated with high dose chemotherapy followed by bone marrow transplantation. In the first two patients, high dose ACNU was used for the treatment without combination with other drugs. This showed severe side effects such as intratumorous bleeding on the 18th day of treatment in the first case and pulmonary fibrosis on the 35th day of treatment in the second case. Considering these results, we considered another treatment schedule which consisted of high dose ADM (100 mg/m2), VCR (1.5 mg/m2), CDDP (80 mg/m2 × 4) and Ex (800 mg/m2) within seven days.
Six patients were treated with this schedule and the results indicated that two patients had a partial response (more than 50% reduction of tumour size measured by CT scan), one had a complete remission (no tumour detected by CT scan), two showed no change and one, progression of the lesion.
The patients recovered from the suppression of bone marrow function after the bone marrow transplantation as indicated. Granulocytes and platelets in blood began to increase from 10 to 14 days after the transplantation and became normal within three weeks after this.
Serial measurements of S-GOT and alkaline phosphatase revealed reversible elevation, if any, within four weeks of the treatment.
The number of our cases is still small, but results showed that autologous bone marrow transplantation made high dose chemotherapy possible.
The necessity for consideration of the blood-brain barrier for this treatment is also discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Burger, P. C., E. Kamenar, S. C. Schold: Encephalomyelopathy following high-dose BCNU therapy. Cancer 48 (1981) 1318–1327
Cooperative study group of phase 1. study on ACNU: Phase 1 study of 1-(4-amino-2-methyl-5-pyrimidyl)-methyl-3-(2-chlorethyl)-3-nitrosourea hydrochloride (ACNU). Jap. J. Clin. Oncol. 6 (1976) 55–62.
Durant J. R., M. J. Norgard, T. M. Murad: Pulmonary toxicity associated with bis-chloroethyl-nitrosourea (BCNU). Ann. Intern. Med. 90 (1979) 191–194
Hochberg, F. H., L. M. Parker, T. Takvorian: Highdose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J. Neurosurg. 54 (1981) 455–460
Levin, V. A., M. Freedman-Dove, H. D. Landahl: Permeability characteristics of brain adjacent to tumours in rats. Arch. Neurol. 32 (1975) 785–791
Levin, V. A., C. B. Wilson, R. Davis: A phase III study comparison of BCNU, hydroxyurea and radiation therapy for treatment of primary malignant gliomas. J. Neurosurg. 51 (1979) 526–532
Masuda, H., K. Kimura, T. Okada: Toxicological studies of CS-439 (ACNU). Ann. Rep. Sankyo Res. Lab. 29 (1977) 118–137
Rall, D. D., C. G. Zubrod: Mechanism of drug absorption and excretion. Passage of drugs in and out of the central nervous system. Ann. Rev. Pharmacol. 2 (1962) 109–128
Saito, Y., Y. Nakaya, K. Muraoka: Chemotherapy of brain tumours with nitrosourea derivatives (ACNU). Gan to Kagakuryoho 5 (1978) 779–794
Schabel, M. F., D. J. Johnston, S. G. McCaleb: Experimental evaluation of potential anticancer agents, VIII: Effect of certain nitrosourea on intracerebral L1210 leukemia. Cancer Res. 23 (1963) 725–733
Schacht, R. G., D. S. Baldwin: Chronic interstitial nephritis and renal failure due to nitrosourea (NU) therapy. Kidney Int. 14 (1978) 661 (abstract)
Shapiro, W. R., J. L. Ausman, D. P. Rall: Studies on the chemotherapy of experimental brain tumors: evaluation of 1,3-bis (2-chlorethyl)-1-nitrosourea, cyclophosphamide, mithramycin and methotrexate. Cancer Res. 30 (1970) 2401–2413
Shibui, S., T. Watanabe, Y. Miki: High dose chemotherapy with autologous bone marrow transplantation for malignant brain tumours. Neurological surgery 11 (1983) 723–729
Shimoyama, M.: The cytocidal action of alkylating agents and anticancer antibiotics againstin vitro cultured Yoshida ascites sarcoma cells. J. Jpn. Soc. Cancer Ther. 10 (1975) 63–72
Spitzer, G., K. A. Dicke, S. Verma: High-dose BCNU therapy with autologous bone marrow infusion: Preliminary observations. Cancer Treat Rep. 63 (1979) 1257–1264
Thomas, E. D., R. Storb: Technique for human marrow grafting. Blood 36 (1970) 507–515
Thompson, G. R., R. E. Larson: A toxicologic comparison of the potency and activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in mice and rats1−3. Toxicol. Appl. Pharmacol. 21 (1972) 405–413
Weiner, R. S., J. A. Tobias, R. A. Yankee: The processing of human bone marrow for cryopreservation and reinfusion. Biomedicine 24 (1976) 226–231
Wasserman, T. H., M. Slavik, S. K. Carter: Clinical comparison of the nitrosoureas. Cancer 36 (1975) 1256–1268
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nomura, K., Watanabe, T., Nakamura, O. et al. Intensive chemotherapy with autologous bone marrow rescue for recurrent malignant gliomas. Neurosurg. Rev. 7, 13–22 (1984). https://doi.org/10.1007/BF01743286
Issue Date:
DOI: https://doi.org/10.1007/BF01743286